Management of Renal Angiomyolipoma (AML)

Initial Assessment and Imaging Confirmation

The European Respiratory Journal recommends surveillance with ultrasound every 3 years for asymptomatic renal AMLs <4 cm detected on ultrasound, without any treatment intervention 1, 2
Ultrasound characteristics of AMLs typically appear hyperechoic and homogeneous due to fat content, though 8% may be isoechoic, as reported by Nature Reviews Nephrology 3, 4
If ultrasound measurements are unreliable, the European Respiratory Journal and Nature Reviews Nephrology suggest obtaining CT or MRI for better characterization 1, 3
CT imaging can detect macroscopic fat appearing as negative density, which is diagnostic, according to Nature Reviews Nephrology 3, 4
MRI is preferred for long-term surveillance in younger patients due to lack of radiation exposure and superior soft tissue characterization, as stated by Nature Reviews Nephrology 3, 4

For small AMLs (<4 cm), the European Respiratory Journal recommends ultrasound surveillance every 3 years, with no treatment indicated unless symptoms develop 1, 2
The risk of spontaneous hemorrhage is very low in this size range, as reported by Praxis Medical Insights 2
For medium AMLs (4-6 cm), Praxis Medical Insights suggests increasing monitoring frequency to every 6-12 months using MRI or CT, and considering treatment if growth rate exceeds 0.5 cm/year 2, 4
For large AMLs (>6 cm), Praxis Medical Insights recommends MRI or CT every 6 months due to higher bleeding risk 4

Intralesional aneurysms ≥5 mm require closer monitoring or treatment due to increased bleeding risk, as reported by the European Respiratory Journal and Nature Reviews Nephrology 1, 3
Growth rate >5 mm/year for fat-poor lesions requires closer monitoring or treatment, according to Nature Reviews Nephrology 3
Symptomatic presentation (flank pain, hematuria, palpable mass) requires treatment, as stated by Praxis Medical Insights 2
Tuberous sclerosis complex (TSC) association requires more frequent monitoring due to faster growth and higher bleeding risk, as reported by Nature Reviews Nephrology and Praxis Medical Insights 2, 3

mTORC1 inhibitors (everolimus or sirolimus) are first-line for fat-poor lesions requiring non-urgent treatment, as recommended by Nature Reviews Nephrology and Praxis Medical Insights 4, 5
Everolimus dosing is 5 mg/day for adults, 2.5 mg/m² for children, with target trough levels of 4-8 ng/mL for sirolimus, as stated by Nature Reviews Nephrology 5
Response to treatment is typically seen within 6-12 months; if no response after 12 months, alternative treatment should be considered, according to Nature Reviews Nephrology 5

Always use the same imaging modality for serial follow-up to accurately assess growth, as different modalities yield different size measurements, as reported by Nature Reviews Nephrology and Praxis Medical Insights 2, 3

Do not assume all hyperechoic lesions are AMLs, as up to 8% of renal cell carcinomas are hyperechoic on ultrasound, according to Nature Reviews Nephrology 3
Do not routinely biopsy fat-poor lesions, as biopsy is only suggested if growth rate exceeds 5 mm/year or lesions fail to respond to mTORC1 inhibition, as stated by Nature Reviews Nephrology 3
Do not discontinue mTORC1 inhibitors abruptly without planning, as discontinuation causes re-growth of AMLs, requiring continued imaging surveillance, according to Nature Reviews Nephrology 5
Do not use ultrasound alone for large or complex lesions, as accuracy decreases significantly in patients with large body habitus or coalescent lesions, as reported by Nature Reviews Nephrology 3